JP2020059759A5 - - Google Patents

Download PDF

Info

Publication number
JP2020059759A5
JP2020059759A5 JP2020000332A JP2020000332A JP2020059759A5 JP 2020059759 A5 JP2020059759 A5 JP 2020059759A5 JP 2020000332 A JP2020000332 A JP 2020000332A JP 2020000332 A JP2020000332 A JP 2020000332A JP 2020059759 A5 JP2020059759 A5 JP 2020059759A5
Authority
JP
Japan
Prior art keywords
crystal
morpholinophenylamino
cyanomethyl
pyrimidin
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020000332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020059759A (ja
JP6840909B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020059759A publication Critical patent/JP2020059759A/ja
Publication of JP2020059759A5 publication Critical patent/JP2020059759A5/ja
Application granted granted Critical
Publication of JP6840909B2 publication Critical patent/JP6840909B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020000332A 2014-06-12 2020-01-06 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩 Active JP6840909B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462011315P 2014-06-12 2014-06-12
US62/011,315 2014-06-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018164680A Division JP6883560B2 (ja) 2014-06-12 2018-09-03 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩

Publications (3)

Publication Number Publication Date
JP2020059759A JP2020059759A (ja) 2020-04-16
JP2020059759A5 true JP2020059759A5 (OSRAM) 2020-12-24
JP6840909B2 JP6840909B2 (ja) 2021-03-10

Family

ID=53674249

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016572271A Active JP6600649B2 (ja) 2014-06-12 2015-06-11 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩
JP2018164680A Active JP6883560B2 (ja) 2014-06-12 2018-09-03 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩
JP2020000332A Active JP6840909B2 (ja) 2014-06-12 2020-01-06 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩
JP2021079700A Active JP7198867B2 (ja) 2014-06-12 2021-05-10 Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩
JP2022202374A Active JP7550205B2 (ja) 2014-06-12 2022-12-19 Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016572271A Active JP6600649B2 (ja) 2014-06-12 2015-06-11 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩
JP2018164680A Active JP6883560B2 (ja) 2014-06-12 2018-09-03 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021079700A Active JP7198867B2 (ja) 2014-06-12 2021-05-10 Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩
JP2022202374A Active JP7550205B2 (ja) 2014-06-12 2022-12-19 Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩

Country Status (37)

Country Link
US (5) US9469613B2 (OSRAM)
EP (3) EP3907219A1 (OSRAM)
JP (5) JP6600649B2 (OSRAM)
KR (1) KR101928225B1 (OSRAM)
CN (2) CN110627728A (OSRAM)
AP (1) AP2016009551A0 (OSRAM)
AR (1) AR100818A1 (OSRAM)
AU (1) AU2015274554B9 (OSRAM)
BR (1) BR112016028749A2 (OSRAM)
CA (1) CA2951883C (OSRAM)
CR (1) CR20160575A (OSRAM)
CU (1) CU20160183A7 (OSRAM)
CY (2) CY1123604T1 (OSRAM)
DK (1) DK3154950T3 (OSRAM)
EA (1) EA032639B1 (OSRAM)
EC (1) ECSP16093323A (OSRAM)
ES (1) ES2822773T3 (OSRAM)
FI (1) FIC20240025I1 (OSRAM)
FR (1) FR24C1030I2 (OSRAM)
HR (1) HRP20201492T1 (OSRAM)
HU (2) HUE051360T2 (OSRAM)
IL (3) IL249038B (OSRAM)
LT (2) LT3154950T (OSRAM)
LU (1) LUC00353I2 (OSRAM)
MA (1) MA40067A (OSRAM)
MX (3) MX374541B (OSRAM)
NL (1) NL301282I2 (OSRAM)
NZ (1) NZ725966A (OSRAM)
PH (1) PH12016502461A1 (OSRAM)
PL (1) PL3154950T3 (OSRAM)
PT (1) PT3154950T (OSRAM)
RS (1) RS61065B1 (OSRAM)
SG (2) SG11201610079VA (OSRAM)
SI (1) SI3154950T1 (OSRAM)
TW (3) TWI729644B (OSRAM)
UY (1) UY36166A (OSRAM)
WO (1) WO2015191846A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018031579A1 (en) 2016-08-10 2018-02-15 Gilead Sciences, Inc. Momelotinib for treating of acvr1 -mediated diseases
WO2019218958A1 (zh) * 2018-05-15 2019-11-21 江苏豪森药业集团有限公司 包含小分子egfr抑制剂的药物组合物及其制备方法
AU2019324155A1 (en) 2018-08-21 2021-02-18 Glaxosmithkline Llc Platelet count-agnostic methods of treating myelofibrosis
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2023010111A1 (en) 2021-07-30 2023-02-02 Sierra Oncology, Inc. Biomarker and patient selection in treatment for myelofibrosis
JP2024532795A (ja) 2021-08-10 2024-09-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー モメロチニブ併用療法
WO2023023473A1 (en) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
CN115957221B (zh) * 2021-10-09 2026-01-06 广东东阳光药业股份有限公司 抗纤维化组合物
WO2023152773A1 (en) * 2022-02-14 2023-08-17 Dr. Reddy's Institute Of Life Sciences Solid forms of momelotinib salts and improved processes for the preparation of momelotinib
CN119704552B (zh) * 2025-02-08 2025-06-13 泰州南洋塑料制品有限公司 一种电池槽注塑模具及边缘毛刺废料处理回收装置

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5559714A (en) 1990-10-22 1996-09-24 Hallmark Cards, Incorporated Method and apparatus for display sequencing personalized social occasion products
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
EP1363702A4 (en) 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
ES2292753T4 (es) 2001-03-29 2009-02-16 Vertex Pharmaceuticals Incorporated Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
JP2005511502A (ja) 2001-09-12 2005-04-28 ヴィレックス リサーチ インコーポレイテッド 固定化した血小板結合剤を有する血管閉塞固相剤
NZ537155A (en) 2002-05-23 2006-09-29 Cytopia Pty Ltd Protein kinase inhibitors
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP2172460A1 (en) 2002-11-01 2010-04-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
US7259161B2 (en) 2002-11-04 2007-08-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
US7348335B2 (en) 2002-11-05 2008-03-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP1799652A1 (en) 2004-10-13 2007-06-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
US8410173B2 (en) 2006-02-28 2013-04-02 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
US8486941B2 (en) 2007-03-12 2013-07-16 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
AU2016200866B2 (en) 2007-03-12 2017-06-22 Glaxosmithkline Llc Phenyl amino pyrimidine compounds and uses thereof
AU2013201306B2 (en) 2007-03-12 2015-11-12 Glaxosmithkline Llc Phenyl Amino Pyrimidine Compounds and Uses Thereof
ES2535166T3 (es) 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
US20100310563A1 (en) 2007-11-30 2010-12-09 Bumm Thomas G P Methods for treating induced cellular proliferative disorders
RU2011108563A (ru) 2008-08-05 2012-09-10 Таргеджен, Инк. (US) Способы лечения талассемии
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US8580749B2 (en) 2009-06-05 2013-11-12 Cell Targeting, Inc. Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
JP5086385B2 (ja) * 2010-03-08 2012-11-28 日立オートモティブシステムズ株式会社 電動パワーステアリング制御装置
MX2012013622A (es) 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
CA2834414A1 (en) * 2011-05-02 2012-11-08 Christopher John Burns Multiple myeloma treatment
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
JPWO2014051056A1 (ja) * 2012-09-28 2016-08-22 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
EP2943489B1 (en) 2013-01-09 2018-04-11 Concert Pharmaceuticals Inc. Deuterated momelotinib
CN103965114B (zh) 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物

Similar Documents

Publication Publication Date Title
IL276948A (en) N- (Cyanomethyl) -4– (2– (4-morpholinophenylamino) pyrimidine-4-il) salts Benzamide hydrochloride
JP4628974B2 (ja) イバブラジン塩酸塩のγ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2014074067A (ja) メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形
JP6008937B2 (ja) １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法
EP1713792B1 (en) SALT OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n- 4-METHYL-3 -(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL-BENZAMIDE MALONATE
JP6830888B2 (ja) Ｊａｋ阻害剤の硫酸水素塩の結晶形およびその製造方法
JP2009506014A5 (OSRAM)
CN101243066A (zh) 甲磺酸伊马替尼的δ和ε晶形
AU2021400317A1 (en) Solid forms of a compound
JP2022535850A5 (OSRAM)
ES2814499T3 (es) Formas en estado sólido de sales de Nilotinib
JP2009517353A5 (OSRAM)
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
JP2024045113A5 (OSRAM)
MX2013010702A (es) Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen.
JP2022553833A5 (OSRAM)
MX2013010634A (es) Cristal mixto de agomelatina (forma-viii), sus metodos de preparacion y aplicaciones y composiciones farmaceuticas que le contienen.
JP2024509276A5 (OSRAM)
TWI374880B (en) A pharmaceutically acceptable salt and solvate of n-[3-[[[2-[(2,3-dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methylmethanesulfonamide and uses thereof
JP2024529533A5 (OSRAM)
WO2011064216A1 (en) Novel salts of rasagiline
CN116916922B (zh) (s,e)-4-(二甲胺基)-n-(3-(4-(2-羟基-1-苯乙胺基)-6-苯基呋喃并[2,3-d]嘧啶-5-基)苯基)丁-2-烯酰胺游离碱的晶型
RU2007123712A (ru) КРИСТАЛЛИЧЕСКИЕ МОДИФИКАЦИИ N-α-(2,4,6-ТРИИЗОПРОПИЛФЕНИЛСУЛЬФОНИЛ)-3-ГИДРОКСИАМИДИНО-(L)-ФЕНИЛАЛАНИН-4-ЭТОКСИКАРБОНИЛПИПЕРАЗИДА И/ИЛИ ЕГО СОЛЕЙ
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
JPWO2010032731A1 (ja) 結晶態様のベンゾイミダゾール化合物又はその塩